Baebies Announces Completion of $10 Million Series B Financing

Innovative Newborn Screening and Pediatric Testing Company Ships 2 Millionth Test ​

DURHAM, NC – October 31, 2017 – Baebies, a growth-stage company that delivers innovative products and services for newborn screening and pediatric testing, today announced that it has secured $10 million in Series B financing in an oversubscribed round anchored by BOE Technology Group Co., Ltd. BOE is a global leader in semiconductor display industry as well as an IoT company providing intelligent interface products and services for information interaction and human health. Baebies also received funding from family offices, with continued support from current investors and the North Carolina Biotechnology Center.

The company also announced the shipment of its 2 millionth test. The company’s SEEKER® product was cleared by the FDA earlier this year and remains the only newborn screening platform authorized for testing for lysosomal storage disorders.

“Baebies digital microfluidic technology is the future of newborn screening methods and we’re proud to collaborate in technology development and play a role in bringing this technology to the global market,” said Lijun Mao, General Manager of BOE Sensor Technology Co., Ltd. “As new technologies arise in healthcare, we want to back the most innovative and promising companies. Baebies has demonstrated rapid growth in the company’s product pipeline and team. The company is a tremendous fit with our Healthcare business, which is committed to offering people-oriented healthcare services by developing mobile healthcare, digital hospitals, regenerative medicine and healthcare park solutions,” said Wei Wu, PhD, Healthcare Investment Director of BOE Ventures.

“This has been an exciting year for Baebies: our team has grown to 60 talented employees, we have secured FDA clearance for our SEEKER screening platform and we recently announced a global distribution partnership with Labsystems Diagnostics to expand the product offerings in the newborn screening space,” said Richard West, Baebies co-Founder and CEO. “We are getting closer to our goal of expanding newborn screening and pediatric testing worldwide to the millions of babies that don’t have access to it.”

“When Richard West and I founded this company in 2014, we set a goal that by 2018 we would provide 2 million chances for a healthy start. Early intervention is critical and we are thrilled to have reached this milestone early. We never lose sight of the fact that every test shipped holds the potential to save a life,” said Vamsee Pamula, PhD, Baebies co-Founder and President. 

About Baebies

At Baebies our sole focus is to advance newborn screening and other pediatric testing worldwide. Baebies is guided by the vision that “everyone deserves a healthy start”. Baebies delivers innovative products and services to make life better for all babies. Baebies offers SEEKER®, the only newborn screening platform authorized by the U.S. FDA for lysosomal storage diseases and is developing FINDER, a rapid near-patient newborn testing solution. FINDER is not available at this time for sale or use in any territory. By bringing new technologies and new tests to the healthcare community, Baebies is providing hope to parents and the chance at a better life to newborns. For more information visit www.baebies.com.